TP53 and mantle cell lymphoma: We similarly assessed the expression of another two important biomarkers, SOX11 (Ek et al., 2008; Xu & Li, 2010) and p53 (Nordstrom et al., 2014; Tessoulin et al., 2017), in MCL cases but found no significant difference among low, intermediate, and high risk group of MCL patients.